Our Scientific & Research Expertise
At Ausovi, Preclinical Validation serves as the decisive bridge between promising lead series and clinical readiness, where we rigorously assess the efficacy, safety, and pharmacokinetic profile of our novel analog compounds using a suite of predictive in vitro and in vivo models. Following successful structure-based lead generation and early optimization, this phase is designed to confirm that selected candidates not only demonstrate robust biological activity but also exhibit the necessary therapeutic index, exposure characteristics, and preliminary safety margins to justify advancement into IND-enabling studies.
We conduct a comprehensive, tiered preclinical validation program that begins with high-throughput in vitro assays—measuring potency, selectivity, mechanism-of-action confirmation, and early cytotoxicity—across disease-relevant cellular systems, including primary patient-derived cells, iPSC-derived models, and organoids. These studies are complemented by advanced functional readouts such as target engagement biomarkers, pathway modulation, and phenotypic reversal in human-relevant contexts.
Once in vitro confidence is established, compounds progress to carefully selected in vivo models chosen to recapitulate key aspects of human disease progression and pathophysiology. Efficacy is evaluated in well-characterized rodent and non-rodent models using clinically relevant endpoints—tumor regression, survival benefit, biomarker modulation, and functional improvement—while simultaneously profiling pharmacokinetics (absorption, distribution, metabolism, excretion) and preliminary tolerability. Dose-response relationships, exposure-efficacy correlations, and therapeutic window assessments are generated under GLP-like conditions to provide quantitative data on dosing regimens and potential liabilities.
Throughout preclinical validation, we integrate early safety screening—cardiovascular, CNS, and genotoxicity panels—and metabolite identification to flag any risks before committing to more resource-intensive toxicology packages. All data are analyzed holistically to support clear go/no-go decisions, refine dosing strategies, and strengthen regulatory and IP narratives.
By owning and executing preclinical validation internally, Ausovi ensures that every candidate entering this phase is tested in models with high translational relevance, generating the robust, reproducible datasets required to de-risk progression, inform clinical trial design, and maximize the probability of success in human studies. This phase is deliberately rigorous and data-intensive because it represents the final gatekeeper before significant clinical investment—ensuring that only compounds with compelling efficacy, manageable safety profiles, and favorable pharmacokinetics advance, thereby protecting resources and delivering the highest possible value to patients and partners.